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Abstract     
Background: The Weight-Specific Adolescent Instrument for Economic Evaluation (WAItE) 
is a new condition-specific patient reported outcome measure that incorporates the views of 
adolescents in assessing the impact of above healthy weight status on key aspects of their 
lives. Presently it is not possible to use the WAItE to calculate quality adjusted life years 
(QALYs) for cost-utility analysis (CUA), given that utility scores are not available for health 
states described by the WAItE.    
Objective: This paper examines different regression models for estimating Child Health 
Utility 9 Dimension (CHU-9D) utility scores from the WAItE for the purpose of calculating 
QALYs to inform CUA.                   
Methods: The WAItE and CHU-9D were completed by a sample of 975 adolescents. Nine 
regression models were estimated: Ordinary Least Squares, Tobit, Censored Least Absolute 
Deviations, Two-Part, Generalised Linear Model, robust MM-estimator, Beta-Binomial, 
Finite Mixture Models, and Ordered Logistic Regression. The mean absolute error (MAE) 
and mean squared error (MSE) were used to assess the predictive ability of the models.     
Results: The robust MM-estimator with stepwise-selected WAItE item scores as explanatory 
variables had the best predictive accuracy. 
Conclusions: Condition-specific tools have been shown to be more sensitive to changes that 
are important to the population for which they have been developed for. The mapping 
algorithm developed in this study facilitates the estimation of health-state utilities necessary 
for undertaking CUA within clinical studies that have only collected the WAItE.            
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1. Introduction                
Increasingly, health benefits from public health interventions are being captured as health-
related quality of life (HRQoL), a multidimensional construct that measures the impact of 
health or disease on physical or psychological functioning [1]. HRQoL can be measured 
directly (through a Standard Gamble or Time Trade Off exercise) or indirectly through 
‘generic’ or ‘condition-specific’ HRQoL instruments. HRQoL instruments can have several 
advantages over direct valuation, such as being more reliable and less complex to administer 
[2]. ‘Generic’ instruments can be seen to assess the core dimensions of health that are 
relevant to all conditions, and  allow comparisons of health benefit across both interventions 
and conditions. In contrast, ‘condition-specific’ instruments focus on the most important 
domains of HRQoL affected by the specific condition, and are usually more sensitive to 
disease-specific improvements in HRQoL.                  
HRQoL instruments can be further classified as ‘preference based’ or ‘non-preference based’. 
Preference-based measures differ from non-preference-based measures in the way the scoring 
algorithms are derived, in that they are estimated from the values that people place on 
different aspects of health rather than a simple summative scoring procedure [3]. Only 
preference based instruments can be used to generate quality adjusted life years (QALYs) for 
use in CUA [4].          
Within paediatric medicine, a number of weight-specific HRQoL instruments have been 
developed for use in adolescence, including the KINDL-obesity module [5], the Impact of 
Weight on Quality of Life-Kids [6], the Moorehead-Ardelt Quality of Life Questionnaire [7], 
Sizing Me Up [8], Youth Quality of Life-Weight [9] and Oxford Paediatric Obesity 
Instrument [10]. However, none of these instruments can be considered preference-based, nor 
were they designed for this purpose. In response to this, a weight-specific HRQoL instrument 
for adolescents, the Weight-Specific Adolescent Instrument for Economic Evaluation 
(WAItE), was developed. The WAItE is a brief 7-item measure incorporating the views and 
experiences of adolescents aged 11-18 years [11]. The WAItE was developed to be suitable 
for undertaking a valuation study, in order to operationalise the calculation of QALYs [4].     
Although specifically designed to be preference based, a valuation study for the WAItE has 
yet to be carried out. In its current form, the WAItE can be used to undertake a cost-
effectiveness analysis of weight management interventions, as WAItE total scores can be 
used to assess the difference in the average scores between two or more groups. However, 
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measuring outcomes in this way makes it difficult to compare outcomes between different 
conditions. Overcoming this comparability problem involves generating a scoring tariff for 
the health states described by the WAItE. This can be done directly via a valuation study or 
indirectly using a mapping algorithm. Directly assigning utility values to WAItE health states 
through a stand-alone valuation study is considered the ‘gold standard’ method [4], however 
such a valuation study can be costly to carry out. Alternatively, a mapping algorithm may be 
used to predict utility scores from responses to a non-preference-based instrument. This 
algorithm can be seen to reflect the statistical relationship between the preference and non-
preference-based instruments, using responses from a population whose responses to both 
instruments have been collected simultaneously [12].           
Although previous studies have conducted a mapping exercise in the adolescent population 
[13] and mapped weight-specific measures of HRQoL to preference based measures in the 
adult population [14], no study has mapped a weight-specific measure of HRQoL onto a 
generic preference based measure in the adolescent population. Given this, the aim of this 
study was to develop a mapping algorithm from the WAItE to the Child Health Utility 9D 
(CHU-9D), a generic preference-based measure of HRQoL in the paediatric population [15], 
therefore facilitating weight-specific adolescent HRQoL to be measured in the context of 
CUA.                 
2 Methods  
2.1 Study Design   
To develop a mapping algorithm from the WAItE to the CHU-9D, an online survey was 
developed with the company Survey Sampling International (SSI) for administration to a 
sample of adolescents aged 11-18 years residing in the United Kingdom (UK). The first 
section of the survey comprised of a series of sociodemographic questions, including age, 
gender, ethnicity, self-reported height and weight and self-assessed health. The second 
section comprised the WAItE and CHU-9D.    
The target sample was 1000, similar to the median sample (1167) found in a recent review of 
the mapping literature [16]. All UK adults from the SSI panel with children between the ages 
of 11-15 (around 15,000) were identified and approached to complete the survey from SSI’s 
participant panel. The 11–15 year old participants were then able to complete the survey 
given the consent of their guardian. Furthermore, around 2,500 16 to 18 year olds were 
directly invited to complete the survey by SSI. The survey was left open until 1,000 
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participants had completed the survey. Respondents to SSI surveys receive an average of 
£0.30 per 5 minute interview. The median time to complete the survey was 6 minutes. A 
quota on weight status was stipulated initially, with an aim of having the 1,000 respondents 
split equally between three weight groups: ‘normal’, ‘overweight’ and ‘obese’. This initial 
quota was done to generate a sample more representative of the individuals who may benefit 
from a weight management interventions, who in this case can be considered the population 
of interest. The survey was approved by Newcastle University's Faculty of Medical Sciences 
Research Ethics Committee (project reference 1262/12643).                              
2.2 Outcome Measures 
WAItE  
The WAItE has seven individual items (relating to tiredness, walking, participation in sports, 
concentration, embarrassment, unhappiness and being treated differently), with a five-point 
Likert scale representing the increasing degrees of severity (ranging from ‘never’ to 
‘always’). The WAItE total score is calculated by summing the answers of the seven items, 
and is scored between 7 and 35 [11]. In analysis, the WAItE total score was reverse coded so 
that a higher WAItE total score indicated a higher quality of life, in line with the CHU-9D.    
CHU-9D  
The CHU-9D has nine individual items (related to being worried, sad, in pain, tired, annoyed, 
schoolwork, sleep, daily routine, and ability to join in activities), each with a five-point Likert 
scale representing increasing degrees of severity (ranging from, for example, ‘I don’t feel 
worried today’ to ‘I feel very worried today’). The instrument has been validated for use in 
both younger children and adolescent populations [15]. We used the scoring algorithm based 
on the preferences of the UK adult general population, meaning that the utility scores are 
bound between 0.33 and 1.     
2.3 Statistical and Econometric Analysis  
Participant characteristics were summarised as means for continuous variables and 
frequencies for categorical variables. Normality of distribution was tested using the Shapiro-
Wilks test [17], and the correlation between the WAItE and the CHU-9D was estimated using 
the Spearman correlation coefficient [18]. This study was conducted in accordance with the 
MAPS (MApping onto Preference-based measures reporting Standards) checklist [19] and 
the recently published ISPOR good practice for outcomes research task report [20]. We first 
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estimated direct mapping models by regressing the WAItE total and item scores directly onto 
the CHU-9D utility scores. An indirect mapping approach was further considered, in which 
the response levels of each CHU-9D item was estimated, before being summed together. This 
method is seen to preserve the main design features of the target instrument [21]. To improve 
predictive performance, age and gender were also included in the econometric specifications, 
as well as quadratic terms to control for non-linear relationships. The four specifications can 
be displayed as:         
 
CHU9DUtility =α0 +β1 ∗ WAItETotal +β2 ∗ WAItETotal
2 +δ1 ∗ AGE +δ2 ∗ GEN
+εi 
(1) 
 
CHU9DUtility =α0 + ∑βi
𝑘
𝑖=1  
∗ WAItEItem + ∑∗
𝑘
𝑖=1  
WAItEItem
2 +δ1 ∗ AGE +δ2 ∗ GEN
+εi 
(2) 
 
CHU9DItem =  α0 +β1 ∗ WAItETotal +β2 ∗ WAItETotal
2 +δ1 ∗ AGE +δ2 ∗ GEN
+εi 
(3) 
 
CHU9DItem =α0 + ∑βi
𝑘
𝑖=1  
∗ WAItEItem + ∑∗ 
𝑘
𝑖=1  
WAItEItem
2 +δ1 ∗ AGE +δ2 ∗ GEN
+εi 
(4) 
 
CHU9DUtility represents the total CHU-9D utility score and CHU9DItem represents one of the 
nine CHU-9D items. Similarly, WAItETotal represents the total WAItE score, and WAItEItem 
represents the selected WAItE items based using the stepwise regression technique, with 𝑘 
representing the number of selected items. The significance level for statistical inference was 
5%.     
Numerous econometric techniques have been used to estimate direct mapping models, with 
the most common being Ordinary Least Squares (OLS), which has been found to work well 
in several previous mapping studies [22, 23]. However, when the distribution of the target 
instrument is non-normal, other regression models are seen as being more appropriate [24]. 
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The Tobit model takes into account the fact that there may be a mass of observations at either 
the upper or lower bound of the distribution [25], while the Censored Least Absolute 
Deviations (CLAD) model [26] takes into account both these bounding issues and 
heteroscedasticity. A two-part logit-OLS regression can also be used to account for the large 
proportion of respondents reporting a utility value of 1. First, a logistic regression model is 
estimated to predict which of the participants have a utility value of 1. Second, an OLS model 
predicting CHU-9D utility scores is estimated for those participants who have a utility score 
below 1. Utility predictions for the two-part model are then estimated using the expected 
value method, which can be displayed as:    
 
Pr(𝑈 = 1) + (1 − Pr(𝑈 = 1)) ∗ 𝑈 (5) 
 
Pr(𝑈 = 1) represents the predicted probability of being in full health from the logit model, 
and 𝑈 represents the predicted utility conditional on having imperfect health, calculated from 
the OLS model.     
The Generalised Linear Model (GLM) allows for skewed distributions of the dependent 
variable. The Pregibon link test and Hosmer-Lemeshow test were used to guide the choice of 
the most appropriate GLM distribution and link function [27]. The robust MM-estimator is 
designed to account for heteroscedasticity and the presence of outliers, and has been found to 
have good performance in the context of mapping studies [28]. The Beta-Binomial (BB) 
model [29] is robust to skewness and can estimate both unimodal and bimodal utilities, and 
has been shown to be superior to OLS regression in the context of mapping [30]. Finite 
Mixture Models (FMMs) are able to combine two or more probability distribution functions, 
and can therefore handle the multimodal distributions of data that commonly characterise 
HRQoL data. Finally, the ordered logit model (OLOGIT) can be used in response mapping 
models to predict the responses to the individual CHU-9D items.  
In line with the previous literature [12, 31], mean squared error (MSE) and mean absolute 
error (MAE) were used to measure the goodness of fit of the models. The MSE is equal to the 
mean of squared errors between the observed CHU-9D utility score and the CHU-9D utility 
score predicted from the model, whereas the MAE is equal to the mean of the absolute 
differences between observed and predicted utility scores. Given the guidance from the 
previous literature [32], more weight was put on the MAE than the MSE when the two 
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statistics conflicted. We also calculated the percentage of the response within 0.03 and 0.05 
of the true utility score.    
2.4 Validation 
Model performance was assessed using an internal dataset and two methods. First, we 
implemented the cross-validation (or ‘k-fold’) method, which has successfully been used in 
several other studies in the mapping literature [33, 34]. This approach first involves randomly 
dividing the sample into five groups. In each instance, 80% of the sample were assigned to 
the estimation sample, with the remaining 20% being assigned to the validation sample. Each 
time, the estimation sample was used to generate the algorithm, which was then used to 
estimate utility values in the validation sample. This process was repeated five times. Second, 
we implemented the ‘random samples’ validation method, which has also been used 
successfully in the mapping literature [31]. In this case, predictive models estimated using the 
entire dataset were validated on random samples of 100, 300 and 500 individuals from the 
sample. The regression model that performed the best in both validation techniques was 
chosen as optimal.                 
3. Results 
3.1 Sample Characteristics  
1000 participants completed the survey. 25 individuals were excluded from analysis due to 
infeasible BMI values, meaning the final sample size was 975. Table 1 summarises the 
characteristics of the respondents. The mean age of the respondents was 15.4 years, and 
50.6% of the respondents were female. From the calculated BMI values, 36.2% of the sample 
were classified as having a ‘normal’ weight, 22.7% of the sample were classified as 
‘overweight’ and 41.1% of the sample were classified as ‘obese’. 57.4% of the adolescents 
reported themselves as having some form illness or disability. Gender was not statistically 
significant in any regression model, and was left out of the final model specification.          
      
[TABLE 1 ABOUT HERE]   
 
The mean WAItE score was 25.39, while the median score was 26. The mean utility of the 
CHU-9D was 0.81, while the median utility was 0.84. The distributions of both the WAItE 
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and the CHU-9D are displayed in the supplementary materials. The distribution of the CHU-
9D utilities was negatively skewed and showed evidence of a ceiling effect, with around 20% 
of the respondents having a utility of over 0.95 and 10.1% of the respondents reporting a 
utility value of 1. As indicated by the Shapiro-Wilk test, both instruments were non-normally 
distributed. Figure 1 displays a scatter plot displaying the relationship between the WAItE 
total score and the CHU-9D utilities. The positive association observed from the scatter plot, 
was corroborated by a strong correlation between the measures (Spearman rank correlation 
coefficient of 0.729).          
 
[FIGURE 1 ABOUT HERE]   
 
3.2 Prediction of CHU-9D Utility Scores 
Table 2 presents the results from the nine regression models and two model specifications in 
the full estimation sample. The Pearson Correlation test [36], Pregibon link test [37] and 
modified Hosmer-Lemeshow test [38] indicated that the most appropriate GLM distribution 
was the gamma distribution with a log link. As it was not obvious from a visual inspection of 
the CHU-9D utility values how many modal components the CHU-9D had, FMMs with 2, 3 
and 4 components were estimated, with the model with the smallest Bayesian Information 
Criteria chosen as the final model.       
Table 2 also presents the results from the key goodness-of-fit statistics for the different 
regression models in the full estimation sample. Although the OLS, GLM and Two-Part 
models in both specifications accurately predicted the mean utility score (0.8056), the 
majority of the remaining models overestimated both the mean utility score. All models 
overestimated the lower limit of the utility score (0.3454).    
 
[TABLE 2 ABOUT HERE] 
 
In Model Specification 1 (which used the WAItE total score to predict the CHU-9D utilities), 
the robust MM-estimator had the lowest MAE (0.0765), while the OLS, Two-Part, GLM and 
FMM had the joint lowest MSE (0.0102). The CLAD model had both the most absolute 
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differences < 0.03 (29.8%), and the most absolute differences < 0.05 (44.9%). In Model 
Specification 2 (which used the individual WAItE items to predict CHU-9D utilities), the 
CLAD model had the lowest MAE (0.0751), while the OLS, Two-Part, GLM and FMM had 
the joint lowest MSE (0.0100). The robust MM-estimator had both the most absolute 
differences < 0.03 (30.4%), and the most absolute differences < 0.05 (48.1%).      
3.3 Validation   
The results from the the full estimation sample were validated using the k-fold and random 
samples validation methods described in sub-section 2.4. Tables 3 and 4 show the results 
from this validation analysis.   
 
[TABLES 3 and 4 ABOUT HERE]  
 
In Model Specification 1, the GLM model accurately predicted the mean CHU-9D utility 
score the most times, while in Model Specification 2 the Two-Part model accurately 
predicted the mean CHU-9D utility scores the most times. Overall, the item level 
specifications (Model Specification 2) performed better than the total score specifications 
(Model Specification 1) in terms of both MAE and MSE. The MAE ranged from 0.0680 
(robust MM-estimator in Model Specification 2 and the third random sample) to 0.1201 
(OLOGIT model in Model Specification 1 and first random sample), while the MSE ranged 
from 0.0088 (Two-Part, GLM and BB models in Model Specification 2 and third random 
sample) to 0.0261 (OLOGIT model in Model Specification 1 and the first random sample). 
The results in Tables 3 and 4 indicate that when all regression models were assessed using 
MAE, the robust MM-estimator in Model Specification 2 had the best predictive ability (best 
performing model in all three random samples), while the Two-Part model in Model 
Specification 2 was the best in terms of MSE (best performing model in the k-fold validation 
and the first and second random samples).                
3.4 Best Performing Models    
On the basis of their performance in the full estimation sample and all four validation 
samples, the Two-Part Model in Model Specification 2 and the robust MM-estimator in 
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Model Specification 2 were chosen as the two best performing models. Detailed performance 
statistics for these models are presented in Tables 5.   
 
[TABLE 5 ABOUT HERE]   
 
When the two best performing models were compared in terms of the MAE, the robust MM-
estimator had a lowest value in the full sample and all four validation samples. When 
compared in terms of the MSE, the Two-Part model had the lowest value in the full sample, 
the k-fold validation sample and random sample 1. The robust MM-estimator had the lowest 
MSE value in the random sample 3. In random sample 2, both estimators had a MSE of 
0.0093. The Two-Part model predicted the observed mean CHU-9D utility better than the 
robust MM-estimator in the full sample, k-fold validation sample and random sample 1, 
whereas the robust MM-estimator predicted the observed mean CHU-9D utility better in 
random sample 2 and random sample 3. The robust MM-estimator had the highest number of 
absolute differences between 0.03 and 0.05 of the mean in the full sample and all four 
validation samples. On the basis of these results, we propose using the robust MM-estimator 
with individual WAItE item scores as explanatory variables to predict CHU-9D utility scores 
from the WAItE.             
The distribution of the MAE and MSE for the two best performing models across the range of 
CHU-9D utility scores was also examined, with these results displayed in the supplementary 
materials. For the Two-Part model, the smallest error in terms of MAE and MSE was found 
in the 0.7-0.8 range. For the robust MM-estimator, the smallest error was found in the 0.9-1 
range. For both the Two-Part and robust MM-estimators, the largest errors were found in the 
sub-sample of individuals with a CHU-9D utility score below 0.7.  
3.5 Mapping Equations  
The regression model coefficients for predicting the CHU-9D utility scores from the WAItE 
using the two best performing regression models are displayed in the supplementary 
materials. Based on the findings from the results from section 3.4, the optimal algorithm for 
calculating CHU-9D utility scores from the can be shown algebraically as:  
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0.4798967 + (0.0107895  ∗  𝑊𝐴𝐼𝑡𝐸_𝑇𝑖𝑟𝑒𝑑)  +  (0.015773  ∗  𝑊𝐴𝐼𝑡𝐸_𝑊𝑎𝑙𝑘𝑖𝑛𝑔) 
+  (0.0231428  ∗  𝑊𝐴𝐼𝑡𝐸_𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛)  +  (0.0131602  
∗  𝑊𝐴𝐼𝑡𝐸_𝐸𝑚𝑏𝑎𝑟𝑟𝑎𝑠𝑠𝑒𝑑)  +  (0.0288246 ∗  𝑊𝐴𝐼𝑡𝐸_𝑈𝑛ℎ𝑎𝑝𝑝𝑦) 
+ (0.0244563 ∗  𝑊𝐴𝐼𝑡𝐸_𝑇𝑟𝑒𝑎𝑡𝑒𝑑 𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑡)  +  (−0.006123  ∗  𝐴𝑔𝑒) 
 
For example, an 11 year-old adolescent who reports ‘never’ to all six of the included WAItE 
items would have an estimated CHU-9D utility value of 0.9932757:   
 
0.4798967 + (0.0107895  ∗  5) +  (0.015773  ∗  5) +  (0.0231428  ∗  5)
+  (0.0131602  ∗  5) + (0.0288246 ∗ 5) + (0.0244563 ∗  5)
+  (−0.006123  ∗ 11) =  0.9932757 
 
Whereas, an 18 year old adolescent who reports ‘always’ to all six of the included WAItE 
items would have an estimated CHU-9D utility value of 0.4858994:  
 
0.4798967 + (0.0107895  ∗  1) +  (0.015773  ∗  1) +  (0.0231428  ∗  1)
+  (0.0131602  ∗  1) + (0.0288246 ∗ 1) + (0.0244563 ∗  1)
+  (−0.006123  ∗ 18) =  0.4858994 
 
The variance-covariance matrix for this model and a plot of the predicted CHU-9D utilities 
against the observed utilities can be found in the supplementary materials.      
4. Discussion    
The purpose of this study was to develop a mapping algorithm to estimate CHU-9D utility 
scores from the WAItE, enabling the derivation of weight-specific health state utilities for 
adolescents. This algorithm allows the costs and benefits of weight management interventions 
for adolescents to be compared to interventions undertaken in different settings, and therefore 
promotes allocative efficiency in health care decision making.   
13 
 
In accordance with recent guidance [19, 20], numerous regression models were estimated to 
establish the most appropriate algorithm for predicating CHU-9D utilities from the WAItE. 
The robust MM-estimator using stepwise selected WAItE item scores as explanatory 
variables was found to be the most accurate. The values of the MAE and MSE statistics 
obtained from this preferred model can be considered low compared to similar studies in the 
literature [31, 39, 40]. However, it should be noted that several other regression models, in 
particular the Two-Part, GLM and OLS models, generated similar estimates to those from the 
robust MM-estimator. The response mapping models (using ordered logits) performed 
poorly, with this poor performance likely due to the small number of observations in several 
CHU-9D and WAItE items.       
Similar to several other studies in the literature, almost all the estimators overestimated the 
lower bound of the CHU-9D utility, and some over predicted the upper bound of 1. Although 
this over prediction is a difficult issue to circumvent, several studies [41, 42] have argued that 
predicted values outside the theoretical limit can be dealt with by truncating them to the 
boundary value. However, further analysis (available on request) displayed that assigning 
values above 1 a value of 1 made no difference to the results.         
There are several strengths to this study. First, we estimated an exhaustive number of 
regression models to determine the most appropriate algorithm. Second, as displayed in 
Figure 1, the target and source instruments overlap adequately in the overall concepts 
measured. A strong correlation between the target and source instruments has previously 
been found to be an important determinant of a successful mapping analysis [43].        
However, there are also some potential shortcomings. First, our data was gathered was from 
an online survey. Although this allowed us to achieve a higher sample size that would have 
been possible using face to face interviews, it is possible that the children did not complete 
the survey themselves. However, given the increasing use of internet surveys and the 
relatively large sample size, we would assume that this recruitment method is acceptable, and 
that all recruitment methods have individual shortcomings. Second, alike several other 
mapping studies [33, 34], an external dataset was unavailable for use, and therefore we used 
in-sample validation. Future research should test the algorithm generated in this study in an 
external dataset to ensure validity.        
Third, a quota was applied to the estimation sample to oversample those adolescents whose 
BMI fell into the ‘overweight’ and ‘obese’ weight status categories, and therefore we did not 
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have an estimation sample that was nationally representative according to weight status. Due 
to the purposive nature of the sampling, the mapping algorithm developed in this study is 
specifically aimed to represent the ‘normal’ ‘overweight’ and ‘obese’ weight categories 
equally, in order to be more representative of those individuals who may be expected to 
benefit from a weight management intervention.         
Fourth, potentially due to the nature of the sample, an unusually high number of respondents 
(57.2%) reported themselves as having some form illness or disability, compared to a 
national average of around 12%, as reported in the 2015 Labour Force Survey [44]. Finally, it 
must be noted that the generated algorithm had a higher level of error for those adolescents 
with a lower HRQOL.              
5. Conclusion   
When a preference based instrument is not included in a study, mapping from a non-
preference based instruments to obtain health state utilities can be seen as the second best 
alternative. This study developed an algorithm to map CHU-9D utility scores from the 
WAItE, a newly developed measure of weight-specific HRQoL for use in adolescents, and is 
the first study to map from a weight-specific HRQoL measure to a generic preference based 
measure in the adolescent population. Our results show that it is possible to predict CHU-9D 
utility scores from the WAItE, with the best results obtained when utilising the robust MM-
estimator with stepwise selected WAItE item scores as predictors. This algorithm may be 
applied for the prediction of CHU-9D utilities, thereby facilitating the calculation of QALYs 
for assessing the relative cost-effectiveness of public health interventions and weight loss 
programmes specifically targeted at the adolescent population.                
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Figure 1- Correlation between the WAItE Total Score and the CHU-9D Utility Score 
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Table 1- Participant Characteristics (N = 975)    
Column 1 2 3 
Characteristic n (%) WAItE Total Score CHU-9D Utility Score 
Full Sample (%) 975 (100%) -  - 
Mean (SD) - 25.39 (5.99) 0.81 (0.14) 
Median (IQR) - 26.00 (21.00-30.00)  0.84 (0.70-0.92) 
Gender 
Males 482 (%) 26.25 (5.72) 0.82 (0.14) 
Females 493 (%) 24.55 (6.14) 0.79 (0.15) 
Age 
11-15 361 (%) 28.60 (5.43) 0.88 (0.12) 
16-18 614 (%) 23.50 (5.48) 0.76 (0.14) 
Ethnicity  
White British/Irish 741 (76.00%) 25.70 (6.14) 0.82 (0.14) 
Asian or Asian British 80 (8.21%) 24.59 (5.23) 0.77 (0.14) 
Black Caribbean/African 46 (4.72%) 27.32 (4.87) 0.83 (0.13) 
Chinese/East Asian 56 (5.74%) 20.16 (3.46) 0.66 (0.09) 
Mixed Ethnicity 43 (4.41%) 26.67 (4.87) 0.82 (0.12) 
Other 9 (0.92%) 23.55 (6.00) 0.77 (0.16) 
Weight Status    
Normal 353 (36.21%) 27.10 (5.64) 0.84 (0.14) 
Overweight 221 (22.67%) 26.10 (5.67) 0.81 (0.14) 
Obese 401 (41.13%) 23.49 (5.93) 0.78 (0.14) 
Self-Assessed Weight    
Very Overweight 97 (9.95%) 19.66 (4.81) 0.68 (0.11)  
Moderately Overweight 141 (14.46%) 22.15 (5.74) 0.75 (0.14) 
Slightly Overweight 251 (25.74%) 24.23 (5.08) 0.78 (0.13) 
About the right Weight 418 (42.87%) 28.26 (5.16) 0.87 (0.13) 
Slightly Underweight 59 (6.05%) 27.33 (5.40) 0.84 (0.14) 
Moderately 
Underweight 
7 (0.72%) 25.86 (4.67) 0.74 (0.15) 
Very Underweight 2 (0.21%) 22.5 (6.36) 0.69 (0.44) 
Self- Assessed Health     
Excellent 168 (17.23%) 29.95 (4.72) 0.92 (0.10) 
Very Good 275 (28.21%) 27.58 (5.03) 0.86 (0.11) 
Good 313 (32.10%) 23.71 (5.29) 0.77 (0.13) 
Fair 157 (16.10%) 21.96 (5.36) 0.72 (0.14) 
Poor 62 (6.36%) 20.48 (5.81) 0.68 (0.16) 
Illness or Disability    
Yes 560 (57.44%) 23.06 (5.68) 0.75 (0.14) 
No 415 (42.56%) 28.54 (4.85) 0.88 (0.11) 
* As per Cole et al [34], individuals in the 85th percentile of the weight distribution for their age and gender were classed as overweight, 
and those in the 95th percentile were classed as being obese.   
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Table 2- Goodness-of-fit results from the full estimation sample (N =975)  
Column 1 2 3 4 5 6 7 
Econometric Model Mean 
(SD) 
 Min Max MAE MSE Abs diff 
<0.03 
Abs diff 
<0.05 
Observed 0.8056 
(0.1440) 
0.3454  1 - - - - 
Model Specification 1- Mapping from WAItE Total Score  
 
1. OLS 0.8056 
(0.1025) 
0.4953 0.9902 0.0775 0.0102 26.5% 
 
42.8% 
 
2. Tobit 0.8125 
(0.1113) 
0.4769 1.0152 0.0767 0.0103 27.7% 
 
44.8% 
 
3. CLAD 0.8200 
(0.1089) 
0.4891 1.0129 0.0768 0.0105 29.8% 
 
44.9% 
 
4. Two-Part 
 
0.8056 
(0.1034) 
0.5086 0.9864 0.0772 0.0102 26.5% 
 
43.4% 
 
5. GLM   0.8056 
(0.1025) 
0.5392 1.0057 0.0771 0.0102 26.7% 
 
43.1% 
 
6. MM 0.8192 
(0.1046) 
0.5004 1.0021 0.0765 0.0104  29.1% 
 
43.9% 
 
7. BB 
 
0.8136 
(0.0816) 
0.4962 0.9273 0.0824 0.0112 21.5% 
 
37.3% 
 
8. FMM 0.8077 
(0.0985) 
0.5102 0.9864 0.0777 0.0102 27.2% 
 
41.6% 
 
9. OLOGIT  0.9033 
(0.1193) 
0.3779 1 0.1179 0.0244 19.6% 33.6% 
Model Specification 2- Mapping from Individual WAItE Items    
  
1. OLS 0.8056 
(0.1037) 
0.4944 0.9931 0.0760 0.0100 28.0% 43.7% 
2. Tobit 0.8125 
(0.1126) 
0.4770 1.0238 0.0757 0.0101 29.4% 45.2% 
3. CLAD 0.8160 
(0.1092) 
0.4908 1.0071 0.0751 0.0102 29.1% 47.6% 
4. Two-Part 
 
0.8056 
(0.1040) 
0.5067 0.9909 0.0759 0.0100 28.0% 44.6% 
5. GLM 0.8056 
(0.1039) 
0.5381 1.008 0.0758 0.0100 28.3% 44.4% 
6. MM 0.8181 
(0.1083) 
0.4859 0.9933 0.0752 0.0103 30.4% 48.1% 
7. BB 
 
0.8138 
(0.0831) 
0.4968 0.9273 0.0813 0.0109 21.6% 38.6% 
8. FMM 0.8087 
(0.0979) 
0.5160 0.9925 0.0766 0.0100 26.4% 42.7% 
9. OLOGIT 0.8957 
(0.1193) 
0.4012 1 0.1117 0.0227 20.9% 36.2% 
CHU-9D – Child Health Utility 9D; MAE – mean absolute error; MSE – mean squared error. Numbers in bold are the best value in each 
column. For column 1, this is the closest value to the observed mean CHU-9D utility. For columns 2 & 3 this is the closest value to the 
observed minimum and maximum CHU-9D utility. For columns 4 & 5 this is the lowest MAE/MSE value. For columns 6 & 7 this is the highest 
number of absolute differences lower than 0.03/0.05.  
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Table 3- Goodness-of-fit results from the validation analyses (Model Specification 1) 
 k-fold validation (N =975)   Random sample 1 (n=500)  Random sample 2 (n=300) Random sample 3(n=100) 
 Observed =  0.8056 Observed = 0.8090 Observed = 0.8146 Observed = 0.8136 
Column 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
 Mean 
Utility 
MAE MSE % 
Abs 
diff< 
0.03  
% 
Abs 
diff< 
0.05 
Mean 
Utility 
MAE MSE % Abs 
diff< 
0.03  
% Abs 
diff< 
0.05 
Mean 
Utility 
MAE MSE % Abs 
diff< 
0.03  
% Abs 
diff< 
0.05 
Mean 
Utility 
MAE MSE % Abs 
diff< 
0.03  
% Abs 
diff< 
0.05 
 
OLS 0.8069 0.0776 0.0103 26.5% 42.7% 0.8101 0.0805 0.0108 23.2% 41.2% 0.8089 0.0767 0.0098 25.0% 42.3% 0.8029 0.0743 0.0095 33.0% 48.0% 
 
Tobit 0.8124 0.0769 0.0104 27.8% 44.6% 0.8173 0.0799 0.0110 24.4% 43.6% 0.8161 0.0753 0.0098 26.7% 43.0% 0.8097 0.0744 0.0099 33.0% 49.0% 
 
CLAD 0.8167 0.0769 0.0104 28.3% 44.7% 0.8277 0.0780 0.0112 28.0% 43.0% 0.8226 0.0749 0.0099 26.3% 42.7% 0.8154 0.0724 0.0095 33.0% 51.0% 
 
Two-
Part 0.8128 0.0767 0.0103 28.2% 45.1% 0.8102 0.0804 0.0108 23.2% 42.0% 0.8091 0.0761 0.0098 25.3% 42.3% 0.8030 0.0744 0.0096 31.0% 48.0% 
 
GLM 0.8056 0.0772 0.0102 27.1% 42.9% 0.8101 0.0803 0.0108 23.4% 41.0% 0.8091 0.0759 0.0097 25.0% 42.0% 0.8030 0.0751 0.0097 31.0% 47.0% 
 
MM 0.8191 0.0767 0.0104 28.6% 44.1% 0.8240 0.0794 0.0111 27.0% 43.0% 0.8224 0.0743 0.0098 30.0% 44.7% 0.8160 0.0721 0.0095 34.0% 50.0% 
 
BB 0.8137 0.0825 0.0112 21.4% 37.5% 0.8172 0.0842 0.0117 22.2% 38.0% 0.8157 0.0823 0.0108 19.3% 26.0% 0.8109 0.0743 0.0090 27.0% 44.0% 
 
FMM 0.8076 0.0779 0.0103 26.2% 41.8% 0.8120 0.0805 0.0108 24.2% 40.0% 0.8109 0.0770 0.0099 25.0% 42.0% 0.8052 0.0737 0.0094 33.0% 47.0% 
 
OLOGIT 0.9028 0.1182 0.0244 19.5% 33.2% 0.9098 0.1201 0.0251 19.2% 32.2% 0.9053 0.1108 0.0220 21.7% 36.7% 0.8989 0.1124 0.0200 14.0% 32.0% 
CHU-9D – Child Health Utility 9D; MAE – mean absolute error; MSE – mean squared error. Numbers in bold are the best value in each column. For columns 1, 6, 11 & 16 this is the closest value to the observed mean CHU-9D utility. For 
columns 2, 7, 12 & 17 this is the lowest MAE value. For columns 3, 8, 13 & 18 this is the lowest MSE value.  For columns 4, 9, 14 & 19 this is the highest number of absolute differences lower than 0.03. For columns 5, 10, 15 & 20 this is the 
highest number of absolute differences lower than 0.05.   
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Table 4- Goodness-of-fit results from the validation analyses (Model Specification 2) 
 k-fold validation (N = 975)  Random sample 1 (n=500)   Random sample 2 (n=300) Random sample 3 (n=100) 
 Observed = 0.8056 Observed = 0.8090   Observed = 0.8146 Observed = 0.8136 
 Mean 
Utility 
MAE MSE Abs 
diff< 
0.03  
Abs 
diff< 
0.05 
Mean 
Utility 
MAE MSE Abs 
diff< 
0.03  
Abs 
diff< 
0.05 
Mean 
Utility 
MAE MSE Abs 
diff< 
0.03  
Abs 
diff< 
0.05 
Mean 
Utility 
MAE MSE Abs 
diff< 
0.03  
Abs 
diff< 
0.05 
 
OLS 0.8061 0.0770 0.0102 28.0% 42.8% 0.8120 0.0785 0.0105 25.8% 41.8% 0.8109 0.0747 0.0093 25.0% 41.7% 0.8035 0.0725 0.0090 32.0% 49.0% 
 
Tobit 0.8130 0.0768 0.0104 28.7% 44.7% 0.8195 0.0785 0.0107 27.4% 43.2% 0.8184 0.0737 0.0094 27.0% 45.0% 0.8100 0.0742 0.0096 29.0% 47.0% 
 
CLAD 0.8151 0.0758 0.0104 30.1% 47.3% 0.8247 0.0777 0.0109 28.6% 45.8% 0.8250 0.0722 0.0093 29.0% 47.7% 0.8168 0.0701 0.0089 34.0% 51.0% 
 
Two-
Part 0.8057 0.0764 0.0101 28.5% 44.4% 0.8120 0.0783 0.0105 25.4% 43.2% 0.8112 0.0743 0.0093 25.0% 45.3% 0.8040 0.0723 0.0091 32.0% 49.0% 
 
GLM 0.8060 0.0769 0.0102 27.4% 42.7% 0.8120 0.0784 0.0105 25.0% 42.6% 0.8110 0.0740 0.0093 26.7% 42.7% 0.8038 0.0737 0.0092 31.0% 46.0% 
 
MM 0.8181 0.0760 0.0104 29.3% 46.3% 0.8247 0.0777 0.0109 28.8% 47.2% 0.8232 0.0720 0.0093 31.7% 47.0% 0.8177 0.0680 0.0087 37.0% 55.0% 
 
BB 0.8140 0.0818 0.0110 21.3% 38.2% 0.8187 0.0832 0.0115 21.8% 39.0% 0.8177 0.0805 0.0104 20.0% 37.0% 0.8118 0.0723 0.0085 26.0% 46.0% 
 
FMM 0.8078 0.0768 0.0101 26.4% 42.5% 0.8148 0.0789 0.0106 24.4% 41.4% 0.8137 0.0754 0.0095 23.3% 42.7% 0.8066 0.0723 0.0090 29.0% 47.0% 
 
OLOGIT 0.8953 0.1117 0.0226 21.3% 36.3% 0.8957 0.1144 0.0239 20.6% 35.2% 0.8957 0.1052 0.0212 23.0% 39.0% 0.8957 0.1062 0.0188 16.0% 34.0% 
CHU-9D – Child Health Utility 9D; MAE – mean absolute error; MSE – mean squared error. Numbers in bold are the best value in each column. For columns 1, 6, 11 & 16 this is the closest value to the observed mean CHU-9D utility. For 
columns 2, 7, 12 & 17 this is the lowest MAE value. For columns 3, 8, 13 & 18 this is the lowest MSE value.  For columns 4, 9, 14 & 19 this is the highest number of absolute differences lower than 0.03. For columns 5, 10, 15 & 20 this is the 
highest number of absolute differences lower than 0.05.  
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Table 5- Model performance for best-fitting models  
Estimation 
Method 
Observed 
CHU-9D 
Mean (SD) 
Mean Min P.25 Median P.75 Max MAE MSE % 
Abs diff< 
0.03  
% 
Abs diff< 
0.05 
Two-Part   
Full Sample 0.8056 0.8056 0.5067 0.7419 0.8012 0.8911 0.9909 0.0759 0.0100 28.0% 44.6% 
k-fold Validation  0.8056 0.8057 0.5069 0.7401 0.8012 0.8914 0.9901 0.0764 0.0101 28.5% 44.4% 
Random Sample 1 0.8090   0.8083 0.5067 0.7315 0.8029 0.8918 0.9907 0.0783 0.0105 25.4% 43.2% 
Random Sample 2 0.8146 0.8050 0.5067 0.7400 0.7983 0.8823 0.9877 0.0743 0.0093 25.0% 45.3% 
Random Sample 3 0.8136 0.7984 0.5329 0.7425 0.7952 0.8626   0.9794 0.0723 0.0091 32.0% 49.0% 
MM   
Full Sample 0.8056 0.8181 0.4859 0.7417 0.8221 0.9096 0.9933 0.0752 0.0103 30.4% 48.1% 
k-fold Validation  0.8056 0.8181 0.4861 0.7419 0.8225 0.9099 0.9933 0.0760 0.0104 29.3% 46.3% 
Random Sample 1 0.8090   0.8202 0.4858 0.7421 0.8278   0.9152 0.9933 0.0777 0.0109 28.8% 47.2% 
Random Sample 2 0.8146 0.8177 0.4858 0.7468 0.8239 0.9043 0.9872 0.0720 0.0093 31.7% 47.0% 
Random Sample 3 0.8136 0.8138 0.5090 0.7567 0.8273 0.8901 0.9764 0.0680 0.0087 37.0% 55.0% 
CHU-9D – Child Health Utility 9D; MAE – mean absolute error; MSE – mean squared error.   
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Online Supplementary Materials- Distribution of WAItE Total Score  
 
 
Online Supplementary Materials- Distribution of CHU-9D Utility Score  
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Online Supplementary Materials- Observed vs Predicted CHU-9D Utilities   
 
 
27 
 
Online Supplementary Materials- Mapping equations from the WAItE to CHU-9D utility scoresa  
Independent variables Two-Part (Model Specification 2) Robust MM-estimator 
(Model Specification 2) Logit Model b OLS Model 
WAItE Tired 
 
0.9280337*** 
(0.1451408) 
0.0122953***   
(0.0044152) 
0.0107895** 
(0.0042061) 
WAItE Walking 0.437054* 
(0.2437725) 
0.0102579**   
(0.0045578) 
0.015773** 
(0.0066986) 
WAItE Concentration   0.4776855*** 
(0.1486862) 
0.0262418*** 
(0.0036084) 
0.0231428*** 
(0.0036076) 
WAItE Embarrassed 0.1882361 
(0.2081824) 
0.0144265*** 
(0.0038541) 
0.0131602*** 
(0.0046261) 
WAItE Unhappy 0.3434785 
(0.2650085) 
0.0214737*** 
(0.0047145) 
0.0288246*** 
(0.0061739) 
WAItE Treated Different 0.082201 
(0.2457673) 
0.0180189*** 
(0.0045279) 
0.0244563*** 
(0.0057471) 
Age -0.181171*** 
(0.0553389) 
-0.0065962*** 
(0.0015402) 
-0.006123*** 
(0.0014019) 
Constant  -9.200232*** 
(1.601675) 
0.5226641*** 
(0.0335752) 
0.4798968*** 
(0.0359304) 
Standard errors in parentheses. p < 0.01=***, p < 0.05=**, p < 0.1=* 
a WAItE dimension scores reverse coded so that 1 indicates ‘Always’ and 5 indicates ‘Never’.   
b Dependant variable in Logit Model is a dummy variable with the value of 1 if CHU-9D=1 and 0 otherwise. OLS model 
only conducted on those who reported a CHU-9D utility below 1.       
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Online Supplementary Materials- Distribution of errors according to selected ranges in the CHU-9D utility score 
  
n 
Two–Part (Model 
Specification 1) 
GLM (Model 
Specification 1) 
CLAD (Model 
Specification 2) 
GLM (Model 
Specification 2)  
MAE MSE MAE MSE MAE MSE MAE MSE 
CHU-9D < 0.7 250 0.1158 0.0201 0.1149 0.0199 0.1230 0.0227 0.1125 0.0194 
0.7 < CHU9D < 0.8 179 0.0582 0.0056 0.0568 0.0053 0.0675  0.0073 0.0548 0.0052 
0.8 < CHU-9D < 0.9 247 0.0670 0.0070   0.0673 0.0069 0.0626 0.0065 0.0670 0.0068 
0.9 < CHU-9D < 1 324 0.0662 0.0078 0.0671 0.0080 0.0549 0.0060 0.0664 0.0079 
CHU-9D – Child Health Utility 9D; MAE – mean absolute error; MSE – mean squared error.  
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Online Supplementary Materials- Variance Covariance Matrix from Mapping Algorithm 
 WAItE_Tired WAItE_Walking 
WAItE_Concentrat
ion 
WAItE_Embarass
ed 
WAItE_Unhappy 
 
 
WAItE_Treated_Di
fferent 
 
 
Age 
 
 
Constant 
WAItE_Tired .00001769        
   
WAItE_Walking -.00001179 .00004487    
   
WAItE_Concentrat
ion 
-3.675e-06 -2.145e-06 .00001301   
   
WAItE_Embarass
ed 
-6.904e-07   -.00001378 9.133e-07 .0000214  
   
WAItE_Unhappy -4.201e-06 .00001295 -2.231e-06 -.00001484 .00003812 
   
WAItE_Treated_D
ifferent 
2.579e-06 -.00001727 -7.348e-08 6.717e-06 -.00002437 
 
 
.00003303 
  
Age 5.949e-07 -6.250e-07 1.340e-06 8.062e-07 4.178e-07 
 
 
6.238e-07 
 
 
1.965e-06 
 
Constant .0000149 -.00006815 -.00004512 -8.914e-06 -.00003883 
 
  
 -7.818e-06 
 
 
-.00004078 
 
 
.001291 
 
 
